The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Yuningwei (301166.SZ) terminates the absorption merger of Nanjing Yuningwei with Nanjing Youai.

You Ningwei (301166.SZ) announced that Nanjing You Ningwei (a wholly-owned subsidiary of the company) originally planned to conduct a merger by absorption...

Zhitong FinanceDec 31, 2024 19:51

Youonwei (301166.SZ): Cumulative repurchase of 0.59% of shares

Grain Live 12/2丨 Youningwei (301166.SZ) announced that as of November 30, 2024, the company repurchased a total of 512,900 shares of the company through the special securities account for share repurchase in a centralized auction trading manner, accounting for 0.59% of the total share capital of the company. The highest fill price was 31 yuan/share, the lowest fill price was 24.98 yuan/share, and the total amount paid was 14,148,635 yuan (excluding transaction fees).

Gelonghui FinanceDec 2, 2024 20:04

Shareholder Taili Investment and its concerted parties of Uinovia (301166.SZ) have completed a shareholding reduction of 1.36%.

Uningwei (301166.SZ) announced that the shareholder of the company is Shanghai Entrepreneurship Relay Taili Entrepreneurship Investment Center (Limited Partnership)...

Zhitong FinanceNov 25, 2024 20:51

Unionway: 2024 Third Quarter Report

SZSIOct 29, 2024 00:00 · Announcements

Youniverse (301166.SZ): As of the end of June, Hangzhou Antibody R&D Center has developed more than 1900 SPU products.

On September 13, Gelonhui reported that Youningwei (301166.SZ) held a performance briefing on September 13, 2024 to answer the question "What new investments or collaborations does Youningwei have in product research and development?" The company stated that as of the end of June 2024, the company's Hangzhou antibody research center has accumulated over 1900 R&D products (IVD antibodies, pathological IHC antibodies, companion diagnostic antibodies, and other raw antibodies), and the Nanjing protein research center has accumulated over 1,500 R&D products (drug targets, cytokines, etc.), further enriching the company's proprietary brand products.

Gelonghui FinanceSep 13, 2024 17:42